Eudaimonia Partners’s Omnicell OMCL Stock Holding History

Eudaimonia Partners’s Portfolio OMCL Stock Details OMCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-200	Closed	-$26K	–	1041
2021 Q1	$26K	Hold	200	–	–	0.01%	862
2020 Q4	$24K	Buy	+200	New	+$19.6K	0.01%	810

Other funds holding OMCL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Eudaimonia Partners's OMCL Position: Q2 2021 in Review

Eudaimonia Partners sold out of Omnicell (OMCL) in Q2 2021, closing a stake of 200 shares — an estimated $26K sold.

Eudaimonia Partners first reported a position in OMCL in Q4 2020 and held it in 2 quarters. The position peaked at $26K in Q1 2021. 377 funds tracked by Wall St. Rank hold OMCL as of Q2 2021.

Eudaimonia Partners reported no remaining Omnicell position as of Q2 2021 after selling out during the quarter.
Eudaimonia Partners sold 200 Omnicell shares in Q2 2021, an estimated $26K.
Eudaimonia Partners first reported a position in Omnicell in Q4 2020 and held it in 2 quarters.
Eudaimonia Partners's Omnicell position peaked at $26K in Q1 2021.
377 funds tracked by Wall St. Rank held Omnicell as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.